Catalent Pharma is a renowned brand that has recently acquired Paragon Bioservices, a leading partner in viral vector development and manufacturing within the rapidly growing gene therapy market. This strategic move positions Catalent for long-term growth and allows them to expand their expertise and capabilities in protein development, manufacturing, and supply. Paragon, with its extensive knowledge and industry-leading capabilities, specializes in the development and manufacturing of adeno-associated virus (AAV) vectors, which are widely used as delivery vehicles for gene therapies.

Their Baltimore, MD facility supports a robust pipeline of clinical stage gene therapies, and they have recently opened a state-of-the-art viral vector manufacturing facility to cater to their expanding customer base. Paragon's capabilities include process and analytical development, drug substance and product manufacturing, and expertise in various AAV production platforms. By joining forces, Catalent and Paragon form an integrated powerhouse that provides comprehensive and streamlined solutions for biologics, enabling companies to develop better treatments efficiently and supply them to patients worldwide